OmniAb Earnings Call: Key Takeaways
OmniAb delivered a strong Q3 2026, raising full-year revenue and cash guidance driven by milestone achievements and a major Eli Lilly partnership.
- Call
- Oct 30, 2026, 8:00 AM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All OmniAb, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
OmniAb delivered a strong Q3 2026, raising full-year revenue and cash guidance driven by milestone achievements and a major Eli Lilly partnership.
OmniAb, Inc. reported total revenue of $31.8 million for the nine months ended September 30, 2026, a significant increase from $10.3 million in the prior year period, primarily driven by license and milestone revenue. Despite the revenue growth, the company recorded a net loss of $29.3 million for the first nine months of 2026, though this was an improvement over the $50.6 million net loss reported for the same period in 2025.
OmniAb reported Q3 2026 financial results, featuring revenue of $4.0 million and a net loss of $15.7 million. The company raised its full-year 2026 revenue guidance to $37-$39 million, citing strong licensing execution and momentum from its xPloration and OmniTides technologies.
“Our strong third-quarter 2026 performance reflects our licensing execution and our focus on driving value for our stakeholders within an efficient business model built on highly differentiated technologies.”
Matt Foehr, Chief Executive Officer of OmniAb
“In addition, the expanded commercial launch of xPloration®, the introduction of OmniTides™, and continued progress across our portfolio of milestone- and royalty-bearing partnered programs reinforce our confidence in the durability of our revenue base and our long-term growth potential. Based on our performance to date and our expectation for the remainder of the year, we are again raising our revenue guidance and cash outlook.”
Matt Foehr, Chief Executive Officer of OmniAb